Scheduled for 7:00 a.m. EST on November 19, 2015

FORT WASHINGTON, Pa., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, will host an Analyst and Investor Briefing on Thursday, November 19, 2015 from 7:00 to 9:00 a.m. EST in New York, NY.

For additional information and registration, please email vitae@westwicke.com or call 443-213-0506.

A live audio webcast of the event will be available via the "Investor Relations" page of the Vitae website, www.vitaepharma.com. Please log on through Vitae's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Vitae's website for 90 days following the call.

About Vitae Pharmaceuticals

Vitae Pharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing first-in-class, small molecule drugs for difficult-to-drug disease targets that can potentially address significant unmet medical needs, including programs in autoimmune disorders, atopic dermatitis, Alzheimer's disease and diabetes. This robust and growing portfolio of novel product candidates is generated internally by Contour®, Vitae's proprietary structure-based drug discovery platform.

For additional information, please visit the company's website at www.vitaepharma.com.

CONTACT: INVESTORS:
         Vitae Pharmaceuticals, Inc.
         Richard S. Morris, CPA
         Chief Financial Officer
         (215) 461-2000
         rmorris@vitaerx.com
         
         Westwicke Partners
         John Woolford
         (443) 213-0506
         john.woolford@westwicke.com
         
         MEDIA:
         6 Degrees PR
         Tony Plohoros
         (908) 591-2839
         tplohoros@6degreespr.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.